Pharma News
FDA Grants Priority Review to Dupixent for Uncontrolled Chronic Obstructive Pulmonary Disease
![](https://meefro.com/wp-content/uploads/2024/02/FDA-Grants-Priority-Review-to-Dupixent-for-Uncontrolled-Chronic-Obstructive-780x470.png)
The FDA has assigned a supplemental Biologics License Application submitted by Regeneron and Sanofi for Dupixent in the treatment of COPD with type 2 inflammation with a PDUFA date of June 27, 2024.
Source link
#FDA #Grants #Priority #Review #Dupixent #Uncontrolled #Chronic #Obstructive #Pulmonary #Disease